TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer.
Chromatin
DNA methylation
Gene regulation
Telomerase reverse transcriptase
Thyroid cancer
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
03 Aug 2024
03 Aug 2024
Historique:
received:
26
01
2024
accepted:
25
07
2024
medline:
4
8
2024
pubmed:
4
8
2024
entrez:
3
8
2024
Statut:
epublish
Résumé
DNA hypermethylation and hotspot mutations were frequently observed in the upstream and core promoter of telomerase reverse transcriptase (TERT), respectively, and they were associated with increased TERT expression and adverse clinical outcomes in thyroid cancer. In TERT promoter mutant cancer cells, the hypomethylated TERT mutant allele was active and the hypermethylated TERT wild-type allele was silenced. However, whether and how the upstream promoter methylation regulates TERT expression in TERT mutation-negative cells were largely unknown. DNA demethylating agents 5-azacytidine and decitabine and a genomic locus-specific demethylation system based on dCas9-TET1 were used to assess the effects of TERT upstream promoter methylation on TERT expression, cell growth and apoptosis of thyroid cancer cells. Regulatory proteins binding to TERT promoter were identified by CRISPR affinity purification in situ of regulatory elements (CAPTURE) combined with mass spectrometry. The enrichments of selected regulatory proteins and histone modifications were evaluated by chromatin immunoprecipitation. The level of DNA methylation at TERT upstream promoter and expression of TERT were significantly decreased after treatment with 5-azacytidine or decitabine in TERT promoter wild-type thyroid cancer cells. Genomic locus-specific demethylation of TERT upstream promoter induced TERT downregulation, along with cell apoptosis and growth inhibition. Consistently, demethylating agents sharply inhibited the growth of thyroid cancer cells harboring hypermethylated TERT but had little effect on cells with TERT hypomethylation. Moreover, we identified that the chromatin remodeling protein CHD4 binds to methylated TERT upstream promoter and promotes its transcription by suppressing the enrichment of H3K9me3 and H3K27me3 at TERT promoter. This study uncovered the mechanism of promoter methylation mediated TERT activation in TERT promoter mutation-negative thyroid cancer cells and indicated TERT upstream promoter methylation as a therapeutic target for thyroid cancer.
Sections du résumé
BACKGROUND
BACKGROUND
DNA hypermethylation and hotspot mutations were frequently observed in the upstream and core promoter of telomerase reverse transcriptase (TERT), respectively, and they were associated with increased TERT expression and adverse clinical outcomes in thyroid cancer. In TERT promoter mutant cancer cells, the hypomethylated TERT mutant allele was active and the hypermethylated TERT wild-type allele was silenced. However, whether and how the upstream promoter methylation regulates TERT expression in TERT mutation-negative cells were largely unknown.
METHODS
METHODS
DNA demethylating agents 5-azacytidine and decitabine and a genomic locus-specific demethylation system based on dCas9-TET1 were used to assess the effects of TERT upstream promoter methylation on TERT expression, cell growth and apoptosis of thyroid cancer cells. Regulatory proteins binding to TERT promoter were identified by CRISPR affinity purification in situ of regulatory elements (CAPTURE) combined with mass spectrometry. The enrichments of selected regulatory proteins and histone modifications were evaluated by chromatin immunoprecipitation.
RESULTS
RESULTS
The level of DNA methylation at TERT upstream promoter and expression of TERT were significantly decreased after treatment with 5-azacytidine or decitabine in TERT promoter wild-type thyroid cancer cells. Genomic locus-specific demethylation of TERT upstream promoter induced TERT downregulation, along with cell apoptosis and growth inhibition. Consistently, demethylating agents sharply inhibited the growth of thyroid cancer cells harboring hypermethylated TERT but had little effect on cells with TERT hypomethylation. Moreover, we identified that the chromatin remodeling protein CHD4 binds to methylated TERT upstream promoter and promotes its transcription by suppressing the enrichment of H3K9me3 and H3K27me3 at TERT promoter.
CONCLUSIONS
CONCLUSIONS
This study uncovered the mechanism of promoter methylation mediated TERT activation in TERT promoter mutation-negative thyroid cancer cells and indicated TERT upstream promoter methylation as a therapeutic target for thyroid cancer.
Identifiants
pubmed: 39097722
doi: 10.1186/s12935-024-03459-2
pii: 10.1186/s12935-024-03459-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
271Subventions
Organisme : National Natural Science Foundation of China
ID : 82222051
Organisme : Fundamental Research Funds for the Central Universities, Sun Yat-sen University
ID : 22ykqb05
Informations de copyright
© 2024. The Author(s).
Références
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
pubmed: 38572751
doi: 10.3322/caac.21834
Chen M, Xue J, Sang Y, Jiang W, He W, Hong S, Lv W, Xiao H, Liu R. Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer. BMC Cancer. 2023;23(1):363.
pubmed: 37081420
pmcid: 10120194
doi: 10.1186/s12885-023-10852-z
Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol. 2024;20(2):93–110.
pubmed: 38049644
doi: 10.1038/s41574-023-00920-6
Zeng PYF, Prokopec SD, Lai SY, Pinto N, Chan-Seng-Yue MA, Clifton-Bligh R, Williams MD, Howlett CJ, Plantinga P, Cecchini MJ, et al. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep. 2024;43(3):113826.
pubmed: 38412093
pmcid: 11077417
doi: 10.1016/j.celrep.2024.113826
Xiao X, Chen M, Sang Y, Xue J, Jiang K, Chen Y, Zhang L, Yu S, Lv W, Li Y, et al. Methylation-mediated silencing of ATF3 promotes thyroid Cancer progression by regulating prognostic genes in the MAPK and PI3K/AKT pathways. Thyroid. 2023;33(12):1441–54.
pubmed: 37742107
doi: 10.1089/thy.2023.0157
Zafon C, Gil J, Perez-Gonzalez B, Jorda M. DNA methylation in thyroid cancer. Endocr Relat Cancer. 2019;26(7):R415–39.
pubmed: 31035251
doi: 10.1530/ERC-19-0093
Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38(9):426–34.
pubmed: 23932019
doi: 10.1016/j.tibs.2013.07.001
Liu M, Zhang Y, Jian Y, Gu L, Zhang D, Zhou H, Wang Y, Xu ZX. The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death Dis. 2024;15(1):90.
pubmed: 38278800
pmcid: 10817947
doi: 10.1038/s41419-024-06454-7
Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143–155.
pubmed: 26733501
pmcid: 4750651
doi: 10.1530/ERC-15-0533
Bullock M, Lim G, Zhu Y, Aberg H, Kurdyukov S, Clifton-Bligh R. ETS factor ETV5 activates the mutant telomerase reverse transcriptase promoter in thyroid Cancer. Thyroid. 2019;29(11):1623–33.
pubmed: 31452441
doi: 10.1089/thy.2018.0314
Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018;9(1):579.
pubmed: 29422527
pmcid: 5805723
doi: 10.1038/s41467-018-03033-1
Song YS, Yoo SK, Kim HH, Jung G, Oh AR, Cha JY, Kim SJ, Cho SW, Lee KE, Seo JS, et al. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr Relat Cancer. 2019;26(6):629–41.
pubmed: 30999281
doi: 10.1530/ERC-17-0562
Thornton CEM, Hao J, Tamarapu PP, Landa I. Multiple ETS factors participate in the Transcriptional Control of TERT Mutant promoter in thyroid cancers. Cancers (Basel). 2022;14(2):357.
pubmed: 35053525
doi: 10.3390/cancers14020357
Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172–83.
pubmed: 31285550
pmcid: 6756069
doi: 10.1038/s41388-019-0872-9
Lee DD, Leao R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolonio JD, et al. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest. 2019;129(1):223–9.
pubmed: 30358567
doi: 10.1172/JCI121303
Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49(3):349–57.
pubmed: 28135248
pmcid: 5571729
doi: 10.1038/ng.3781
Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 2013;14(6):534–42.
pubmed: 23598174
doi: 10.1016/S1470-2045(13)70110-4
Castelo-Branco P, Leao R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, et al. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget. 2016;7(36):57726–36.
pubmed: 27437772
pmcid: 5295385
doi: 10.18632/oncotarget.10639
Faleiro I, Apolonio JD, Price AJ, De Mello RA, Roberto VP, Tabori U, Castelo-Branco P. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer. Future Oncol. 2017;13(23):2045–51.
pubmed: 29019414
doi: 10.2217/fon-2017-0167
Leao R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019;144(7):1676–84.
pubmed: 30350309
doi: 10.1002/ijc.31935
Apolonio JD, Dias JS, Fernandes MT, Komosa M, Lipman T, Zhang CH, Leao R, Lee D, Nunes NM, Maia AT, et al. THOR is a targetable epigenetic biomarker with clinical implications in breast cancer. Clin Epigenetics. 2022;14(1):178.
pubmed: 36529814
pmcid: 9759897
doi: 10.1186/s13148-022-01396-3
Wang N, Kjellin H, Sofiadis A, Fotouhi O, Juhlin CC, Backdahl M, Zedenius J, Xu D, Lehtio J, Larsson C. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget. 2016;7(16):21332–46.
pubmed: 26870890
pmcid: 5008288
doi: 10.18632/oncotarget.7237
Li JJ, Zheng PCJ, Wang YZ. The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC). World J Surg Oncol. 2017;15(1):114.
pubmed: 28587656
pmcid: 5461729
doi: 10.1186/s12957-017-1170-z
Paulsson JO, Mu N, Shabo I, Wang N, Zedenius J, Larsson C, Juhlin CC. TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours. Endocr Relat Cancer. 2018;25(7):723–33.
pubmed: 29692346
doi: 10.1530/ERC-18-0050
Montero-Conde C, Leandro-Garcia LJ, Martinez-Montes AM, Martinez P, Moya FJ, Leton R, Gil E, Martinez-Puente N, Guadalix S, Curras-Freixes M, et al. Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers. Clin Transl Med. 2022;12(8):e1001.
pubmed: 35979662
pmcid: 9386325
doi: 10.1002/ctm2.1001
Li S, Xue J, Jiang K, Chen Y, Zhu L, Liu R. TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer. Front Oncol. 2024;14:1325345.
pubmed: 38313800
pmcid: 10834694
doi: 10.3389/fonc.2024.1325345
Lee DD, Komosa M, Nunes NM, Tabori U. DNA methylation of the TERT promoter and its impact on human cancer. Curr Opin Genet Dev. 2020;60:17–24.
pubmed: 32114294
doi: 10.1016/j.gde.2020.02.003
McKelvey BA, Umbricht CB, Zeiger MA. Telomerase Reverse transcriptase (TERT) regulation in thyroid Cancer: a review. Front Endocrinol (Lausanne). 2020;11:485.
pubmed: 32849278
doi: 10.3389/fendo.2020.00485
Stern JL, Paucek RD, Huang FW, Ghandi M, Nwumeh R, Costello JC, Cech TR. Allele-specific DNA methylation and its interplay with repressive histone marks at promoter-mutant TERT genes. Cell Rep. 2017;21(13):3700–7.
pubmed: 29281820
pmcid: 5747321
doi: 10.1016/j.celrep.2017.12.001
Esopi D, Graham MK, Brosnan-Cashman JA, Meyers J, Vaghasia A, Gupta A, Kumar B, Haffner MC, Heaphy CM, De Marzo AM, et al. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. Cell Oncol (Dordr). 2020;43(5):847–61.
pubmed: 32468444
pmcid: 7581602
doi: 10.1007/s13402-020-00531-7
McKelvey BA, Gilpatrick T, Wang Y, Timp W, Umbricht CB, Zeiger MA. Characterization of allele-specific regulation of Telomerase Reverse transcriptase in promoter mutant thyroid Cancer cell lines. Thyroid. 2020;30(10):1470–81.
pubmed: 32228178
pmcid: 7583328
doi: 10.1089/thy.2020.0055
Liu R, Tan J, Shen X, Jiang K, Wang C, Zhu G, Xing M. Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2. Proc Natl Acad Sci U S A. 2021;118(11):e2022779118.
pubmed: 33836600
pmcid: 7980366
doi: 10.1073/pnas.2022779118
Chen Y, Sang Y, Li S, Xue J, Chen M, Hong S, Lv W, Sehgal K, Xiao H, Liu R. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. Transl Oncol. 2024;45:101991.
pubmed: 38728872
pmcid: 11107342
doi: 10.1016/j.tranon.2024.101991
Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, Shu J, Dadon D, Young RA, Jaenisch R. Editing DNA methylation in the mammalian genome. Cell. 2016;167(1):233–47.
pubmed: 27662091
pmcid: 5062609
doi: 10.1016/j.cell.2016.08.056
Liu X, Zhang Y, Chen Y, Li M, Zhou F, Li K, Cao H, Ni M, Liu Y, Gu Z, et al. In situ capture of chromatin interactions by biotinylated dCas9. Cell. 2017;170(5):1028–43.
pubmed: 28841410
pmcid: 6857456
doi: 10.1016/j.cell.2017.08.003
Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, et al. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol Cell Endocrinol. 2017;448:34–40.
pubmed: 28288903
doi: 10.1016/j.mce.2017.03.007
Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, et al. TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. Thyroid. 2019;29(8):1105–14.
pubmed: 31286848
doi: 10.1089/thy.2018.0695
Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–765.
pubmed: 24476079
pmcid: 4191548
doi: 10.1210/jc.2013-3734
Kim TH, Kim YE, Ahn S, Kim JY, Ki CS, Oh YL, Kim K, Yun JW, Park WY, Choe JH, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer. 2016;23(10):813–23.
pubmed: 27528624
doi: 10.1530/ERC-16-0219
Park J, Lee S, Kim K, Park H, Ki CS, Oh YL, Shin JH, Kim JS, Kim SW, Chung JH, et al. TERT promoter mutations and the 8th Edition TNM classification in Predicting the survival of thyroid Cancer patients. Cancers (Basel). 2021;13(4):648.
pubmed: 33562809
doi: 10.3390/cancers13040648
Avin BA, Wang Y, Gilpatrick T, Workman RE, Lee I, Timp W, Umbricht CB, Zeiger MA. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines. Genes Chromosomes Cancer. 2019;58(8):530–40.
pubmed: 30664813
pmcid: 6621557
doi: 10.1002/gcc.22735
Guilleret I, Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res. 2003;289(2):326–34.
pubmed: 14499633
doi: 10.1016/S0014-4827(03)00281-7
Kumari A, Srinivasan R, Wig JD. Effect of c-MYC and E2F1 gene silencing and of 5-azacytidine treatment on telomerase activity in pancreatic cancer-derived cell lines. Pancreatology. 2009;9(4):360–8.
pubmed: 19451745
doi: 10.1159/000212094
Pettigrew KA, Armstrong RN, Colyer HA, Zhang SD, Rea IM, Jones RE, Baird DM, Mills KI. Differential TERT promoter methylation and response to 5-aza-2’-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death. Genes Chromosomes Cancer. 2012;51(8):768–80.
pubmed: 22517724
doi: 10.1002/gcc.21962
Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene. 2002;21(20):3130–8.
pubmed: 12082628
doi: 10.1038/sj.onc.1205419
Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, Herold-Mende C, Wick W, Turcan S. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro Oncol. 2021;23(1):76–87.
pubmed: 32882013
doi: 10.1093/neuonc/noaa207
Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res. 1999;59(24):6087–90.
pubmed: 10626795
Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res. 2000;60(3):537–41.
pubmed: 10676632
Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer. 2002;101(4):335–41.
pubmed: 12209957
doi: 10.1002/ijc.10593
Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res. 2007;67(1):194–201.
pubmed: 17210699
doi: 10.1158/0008-5472.CAN-06-3396
Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, Benhattar J. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007;35(4):1245–56.
pubmed: 17267411
pmcid: 1851636
doi: 10.1093/nar/gkl1125
Rowland TJ, Bonham AJ, Cech TR. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers. Mol Oncol. 2020;14(10):2358–74.
pubmed: 33245585
pmcid: 7530785
doi: 10.1002/1878-0261.12786
Lee DD, Komosa M, Sudhaman S, Leao R, Zhang CH, Apolonio JD, Hermanns T, Wild PJ, Klocker H, Nassiri F, et al. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. J Clin Invest. 2021;131(21):e146915.
pubmed: 34720085
pmcid: 8553568
doi: 10.1172/JCI146915
Lee S, Chang TC, Schreiner P, Fan Y, Agarwal N, Owens C, Dummer R, Kirkwood JM, Barnhill RL, Theodorescu D, et al. Targeted Long-Read Bisulfite sequencing identifies differences in the TERT promoter methylation profiles between TERT Wild-Type and TERT Mutant Cancer cells. Cancers (Basel). 2022;14(16):4018.
pubmed: 36011010
doi: 10.3390/cancers14164018
Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26(37):5433–8.
pubmed: 17694084
doi: 10.1038/sj.onc.1210611
Xia L, Huang W, Bellani M, Seidman MM, Wu K, Fan D, Nie Y, Cai Y, Zhang YW, Yu LR, et al. CHD4 has oncogenic functions in initiating and maintaining epigenetic suppression of multiple tumor suppressor genes. Cancer Cell. 2017;31(5):653–68.
pubmed: 28486105
pmcid: 5587180
doi: 10.1016/j.ccell.2017.04.005
Pratheeshkumar P, Siraj AK, Divya SP, Parvathareddy SK, Alobaisi K, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. CHD4 predicts aggressiveness in PTC patients and promotes Cancer stemness and EMT in PTC cells. Int J Mol Sci. 2021;22(2):504.
pubmed: 33419089
pmcid: 7825451
doi: 10.3390/ijms22020504
Masoodi T, Siraj AK, Siraj S, Azam S, Qadri Z, Albalawy WN, Parvathareddy SK, Al-Sobhi SS, Al-Dayel F, Alkuraya FS, et al. Whole-exome sequencing of Matched Primary and metastatic papillary thyroid Cancer. Thyroid. 2020;30(1):42–56.
pubmed: 31668133
pmcid: 6983753
doi: 10.1089/thy.2019.0052
Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone methylation in ageing and cancer. Nat Rev Mol Cell Biol. 2019;20(10):573–89.
pubmed: 31270442
doi: 10.1038/s41580-019-0143-1
Li Y, Chen X, Lu C. The interplay between DNA and histone methylation: molecular mechanisms and disease implications. EMBO Rep. 2021;22(5):e51803.
pubmed: 33844406
pmcid: 8097341
doi: 10.15252/embr.202051803